Rare diseases
Investigational molecules
Locations
Back to Germany1 191 clinical trials in Munich, Germany across 8 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in GermanyKlinischeStudien.de(opens in a new tab)JNJ-95597528 for Adults with Moderate to Severe Atopic Dermatitis
GermanyCorabotase for Moderate to Severe Glabellar Lines in Adults
GermanyFaricimab for Choroidal Neovascularization Secondary to Pathologic Myopia in Patients with Pathologic Myopia
GermanyA study to evaluate the effectiveness and safety of BFB759 in adults with moderate to severe hidradenitis suppurativa
GermanySacituzumab Tirumotecan in Recurrent or Metastatic Cervical Cancer After Platinum Chemotherapy and Anti-PD-L1 or Anti-PD-1 Therapy
GermanyEfficacy of Cobolimab, Dostarlimab, and Docetaxel in Advanced Non-Small Cell Lung Cancer Post Anti-PD(L)1 Therapy and Chemotherapy
GermanyA Phase 3 Randomized Open-Label Study of Sacituzumab Govitecan Versus Physician's Choice in Recurrent or Persistent Endometrial Cancer Post-Chemotherapy and Immunotherapy
GermanyEfficacy and Safety Evaluation of Litifilimab in Adults with Active Systemic Lupus Erythematosus on Standard Nonbiologic Lupus Care: A Phase 3 Randomized Controlled Trial
GermanyEfficacy and Safety of Maintenance Cabozantinib Plus Best Supportive Care in Pediatric and AYA Patients with Unresectable Residual Osteosarcoma
GermanyStudy of Trontinemab Compared to Placebo for Patients with Early Symptomatic Alzheimer's Disease
GermanyA study testing trontinemab compared to placebo in patients with early Alzheimer's disease including mild cognitive impairment and mild dementia
GermanyStudy of xaluritamig compared to cabazitaxel or androgen receptor therapy for patients with metastatic castration-resistant prostate cancer
GermanyThe busiest research cities in the country
What the registry says about research in the country
In München, clinical trials in oncology and blood cancers focus on improving survival, controlling relapse, and refining treatment strategies for a wide range of cancers.
These studies are testing new combinations and comparative approaches to strengthen cancer control and better support patients with advanced or hard-to-treat disease.
Trials in cardiovascular medicine are examining ways to lower major events, improve post-procedure care, and optimize long-term protection in high-risk patients.
Much of this work aims to improve treatment effectiveness while reducing serious cardiovascular complications.
Respiratory research in this city is broad, with studies centered on chronic lung disease, inflammation, and treatment options for people with difficult-to-control symptoms.
These trials are mainly evaluating whether new therapies can improve breathing, symptom control, and long-term lung outcomes.
Neurological research spans emergency stroke care, chronic neurodegenerative disorders, and therapies aimed at preserving daily function and quality of life.
Research here is exploring better acute treatments, symptom relief, and disease-modifying approaches for progressive neurological conditions.
Several studies address immune-mediated diseases, including skin disorders and systemic inflammatory conditions, with the goal of improving symptom control and reducing flare burden.
These trials are assessing whether newer targeted treatments can provide better and more durable relief for inflammatory disease.
Research in metabolic disease focuses on diabetes control, obesity management, and reduction of long-term cardiometabolic risk.
The overall aim is to test therapies that may improve glucose control, support weight loss, and lower future complications.
Eye disease trials are looking at ways to protect vision and slow progression in conditions that can lead to irreversible damage.
These studies are designed to improve treatment options for patients facing progressive vision loss.
Clinical research in infectious disease includes both prevention and treatment, with attention to viral infection and serious respiratory illness.
These trials aim to strengthen prevention strategies and improve outcomes in infections that can place a heavy burden on patients and healthcare systems.
Studies in urology and kidney disease address both cancer and transplant-related care, along with advanced prostate cancer.
Research in this area is focused on improving treatment effectiveness, organ outcomes, and long-term patient safety.
Trials here cover musculoskeletal disease and persistent pain, seeking better ways to relieve symptoms that often limit mobility and daily activity.
The main goal is to evaluate therapies that may provide stronger and more lasting pain relief.
Several studies in München address rare diseases and childhood cancers, where new treatment approaches are especially important.
These trials are testing ways to improve outcomes for young patients with aggressive or recurrent disease.
Some studies bridge allergy, inflammation, and respiratory disease, reflecting the role of immune pathways in chronic symptoms.
These trials are evaluating targeted treatments that may better control inflammation and reduce flare-ups.
A portion of the trial portfolio does not fit neatly into one specialty, reflecting broad research across overlapping medical conditions and complex patient groups.
These studies often aim to improve overall treatment benefit, safety, and real-world applicability across different patient populations.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
